What is the actual selling price of pazopanib/pazopanib after reimbursement in 2025?
Pazopanib is a multikinase inhibitor approved for the treatment of advanced renal cell carcinoma and chemotherapy-refractory soft tissue sarcoma. The drug is available as an oral tablet and is recommended to be taken once daily, primarily for adults who have already received chemotherapy. The metabolism and elimination process of pazopanib in the body is relatively unique. Its half-life is approximately 31 hours, which means that the time required for the drug concentration to drop to half is 31 hours.
According to estimates, since pazopanib has no active metabolite, its complete elimination requires approximately 5 half-lives. Therefore, the residence time of the drug in the body is approximately 5 to 6.5 days, that is, 124 to 155 hours. This feature allows physicians to better control the frequency of drug use and dosage adjustments when formulating treatment plans to achieve optimal efficacy.

The original drug of pazopanib has been marketed in China and is also listed as a reimbursable drug by medical insurance, but only patients who meet its indications can enjoy the reimbursement policy. The common packaging specifications of this medicine are 30 tablets of 200mg and 30 tablets of 400mg. Its market price is about 3,000 yuan per box. In overseas markets, the price of this original drug may fluctuate around 2,000 yuan per box, which is mainly affected by exchange rates.
In addition, generic pazopanib drugs are also sold in overseas markets. For example, the product produced by a Bangladeshi pharmaceutical factory has ingredients very close to the original drug, but the price is much lower than the original drug. Each box may only cost 500 yuan. However, this price may also be adjusted due to exchange rate changes. In summary, pazopanib provides an important drug option for the treatment of advanced renal cell carcinoma and soft tissue sarcoma, helping patients improve their quality of life.
Reference materials:https://www.votrient.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)